Skip to main content
. 2019 Mar 28;104(11):2206–2214. doi: 10.3324/haematol.2018.214809

Figure 2.

Figure 2.

Patient outcomes. Flow diagram showing outcomes of 450 patients after the achievement of sustained molecular response (MR)-3 (sMR3). The boxes in the lower part of the image contain information about the tyrosine kinase inhibitor (TKI) dose at the time of response loss. LD: lower TKI dose (compared to the standard recommended doses for first or subsequent lines); SD: standard TKI dose; HD: higher TKI dose; sMR4: sustained MR4; pts: patients.